This page has only limited features, please log in for full access.

Unclaimed
Jr. John C. Flickinger
Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 1020 Locust Street, Philadelphia, PA 19107, USA

Basic Info

Basic Info is private.

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Review
Published: 09 April 2020 in Toxins
Reads 0
Downloads 0

The ability of the immune system to precisely target and eliminate aberrant or infected cells has long been studied in the field of infectious diseases. Attempts to define and exploit these potent immunological processes in the fight against cancer has been a longstanding effort dating back over 100 years to when Dr. William Coley purposefully infected cancer patients with a cocktail of heat-killed bacteria to stimulate anti-cancer immune processes. Although the field of cancer immunotherapy has been dotted with skepticism at times, the success of immune checkpoint inhibitors and recent FDA approvals of autologous cell therapies have pivoted immunotherapy to center stage as one of the most promising strategies to treat cancer. This review aims to summarize historic milestones throughout the field of cancer immunotherapy as well as highlight current and promising immunotherapies in development.

ACS Style

Robert D. Carlson; Jr. John C. Flickinger; Adam E. Snook; John Jr. Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy. Toxins 2020, 12, 241 .

AMA Style

Robert D. Carlson, Jr. John C. Flickinger, Adam E. Snook, John Jr. Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy. Toxins. 2020; 12 (4):241.

Chicago/Turabian Style

Robert D. Carlson; Jr. John C. Flickinger; Adam E. Snook; John Jr. 2020. "Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy." Toxins 12, no. 4: 241.

Review
Published: 25 July 2018 in Vaccines
Reads 0
Downloads 0

Listeria monocytogenes, a Gram-positive facultative anaerobic bacterium, is becoming a popular vector for cancer immunotherapy. Indeed, multiple vaccines have been developed utilizing modified Listeria as a tool for generating immune responses against a variety of cancers. Moreover, over a dozen clinical trials testing Listeria cancer vaccines are currently underway, which will help to understand the utility of Listeria vaccines in cancer immunotherapy. This review aims to summarize current views on how Listeria-based vaccines induce potent antitumor immunity and the current state of Listeria-based cancer vaccines in clinical trials.

ACS Style

Jr. John C. Flickinger; Ulrich Rodeck; Adam E. Snook. Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress. Vaccines 2018, 6, 48 .

AMA Style

Jr. John C. Flickinger, Ulrich Rodeck, Adam E. Snook. Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress. Vaccines. 2018; 6 (3):48.

Chicago/Turabian Style

Jr. John C. Flickinger; Ulrich Rodeck; Adam E. Snook. 2018. "Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress." Vaccines 6, no. 3: 48.